A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Raltegravir is the first marketed strand-transfer inhibitor of HIV-1 that was FDA approved in
2007. It is currently one of the preferred treatment regimens for HIV by the Department of
Health and Human Services. It has become a widely used antiretroviral therapy option for HIV
infected patients. It provides good tolerability and a favorable lipid profile for patients
when compared to some other antiretroviral treatment options. Little data is reported about
efficacy in a minority patient population. Moreover, data in an indigent minority population
in the United States has not been aggregated before. Therefore this study will investigate
the efficacy of raltegravir in minority women residing in Houston, TX who are HIV infected.
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston